TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00953017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miralax (PEG 3350)
Description: Miralax 255gm bottle
Study: NCT00559962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733 and atorvastatin
Description: 3 capsules each evening for each 4-week period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733 and fenofibrate
Description: 3 capsules each evening for each 4-week period
Study: NCT00953017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitiza (Lubiprostone)
Description: Amitiza 24mcg gelcap

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulcolax (Bisacodyl)
Description: Bisacodyl 5mg tab x2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely (polyethylene glycol)
Description: Golytely 1 gallon
Study: NCT01920698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous MitraClip Device Implantation
Description: MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system

Intervention type: OTHER
Group type: OTHER
Intervention: control
Study: NCT02350114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Test
Description: Evaluation of walking distance on standardized 6 minute walk test
Study: NCT00741026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg po qhs for 3 days
Description: (1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
Study: NCT00559962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733 and ezetimibe
Description: 3 capsules each evening for each 4-week period
Study: NCT00741026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
Study: NCT05814224

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid biopsy and CT scan
Description: CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation
Study: NCT03410979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737 single dose
Description: GLPG2737 oral suspension, single ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Placebo, oral suspension.
Study: NCT03930524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-Bridge Online Health Coach
Description: A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
Study: NCT03410979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737 multiple dose
Description: GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG2737 multiple dose
Description: Placebo, oral suspension, daily for 14 days
Study: NCT04330066

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound measurement of the endometrial lining
Description: On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound measurement of the endometrial lining
Description: On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
Study: NCT03514446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy duration for 7 days
Description: Antibiotic therapy for seven days
Study: NCT02086734

Intervention type: OTHER
Intervention: Perfusion-CT
Description: 1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT
Study: NCT01198327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Laser
Description: Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
Study: NCT04485026

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local consolidative radiation therapy
Description: All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care radiation therapy
Description: Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
Study: NCT00365326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Catheter-based intracoronary injection
Description: This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
Study: NCT03145727

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency Group
Description: In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Group
Description: In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
Study: NCT01657591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL888
Description: Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
Study: NCT02098434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montreal Imaging Stress Task
Description: Math task developed to induce a stress response in a laboratory setting
Study: NCT01738282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for baclofen)
Study: NCT01891227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
Study: NCT02300194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topic Morphine
Description: Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
Study: NCT03075826

Intervention type: DRUG
Group type: OTHER
Intervention: SGI-110
Description: subcutaneously at a dose of 60 mg/m2
Study: NCT03611595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid
Description: 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
Study: NCT00122954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate
Description: fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soybean oil with 1% fish oil at a daily dose of 6 grams
Study: NCT05310266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
Study: NCT00457249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
Description: 0.5 mL, IM
Study: NCT00062075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study: NCT04424732

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
Study: NCT05310266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
Study: NCT02358746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined endo/epicardial approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stepwise approach
Description: endocardial scar homogenization only at the first VT ablation procedure
Study: NCT01831310

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard (Kabiven)
Description: Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
Study: NCT02012322

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period
Study: NCT01371604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 50 mg tablet administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFN)
Description: Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
Study: NCT01831310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-Glutamine
Description: Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-Omega 3 fatty acid
Description: Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard-glutamine-omega 3
Description: Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
Study: NCT03357458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
Study: NCT00215826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alferon LDO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alferon LDO
Study: NCT02353481

Intervention type: OTHER
Intervention: Heart Failure Management
Study: NCT04607408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF gp120
Description: HIV-1 CH505 transmitted/founder virus Env gp120 immunogen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF gp120
Description: HIV-1 CH505 transmitted/founder virus Env gp120 immunogen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF gp120
Description: HIV-1 CH505 transmitted/founder virus Env gp120 immunogen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF gp120
Description: HIV-1 CH505 transmitted/founder virus Env gp120 immunogen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9% USP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9% USP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9% USP
Study: NCT01371604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to IDX184 50 mg tablet administered orally
Study: NCT03975894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT).
Description: Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% \<30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion.
Study: NCT03629262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study: NCT04110015

Intervention type: DEVICE
Intervention: virtual visual field
Description: Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
Study: NCT03449979

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
Study: NCT01363206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
Description: GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
Study: NCT03095378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: citric acid plus tetracycline
Description: Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy
Description: Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
Study: NCT02072889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Angle
Description: Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated